GlassScriptPhysician profile
Evan H Schwarzwald
NPI 1164414330
$310,642.00
in general payments reported to CMS, 2019-2025
21 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $27K · 2021: $30K · 2022: $63K · 2023: $43K · 2024: $82K · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Travel and Lodging: $5,247 · Food and Beverage: $5,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,326.00 |
| Travel and Lodging | $5,246.78 |
| Food and Beverage | $5,147.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $135,512.52 | 2019-2024 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $63,769.83 | 2019-2024 | Xarelto |
| Amgen INC. | $47,933.35 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,500.27 | 2019-2022 | |
| Amarin Pharma, INC. | $18,964.57 | 2019-2020 | |
| Lilly USA, LLC | $12,094.69 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Medtronic, INC. | $2,771.95 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Linq II |
| Medtronic Vascular, INC. | $2,274.98 | 2019-2020 | |
| Boston Scientific Corporation | $1,287.08 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Astrazeneca Pharmaceuticals LP | $318.64 | 2019-2020 | |
| Intuity Medical INC | $289.43 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cvrx, INC. | $280.30 | 2022-2023 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $141.58 | 2019 | |
| Preventice Services, LLC | $117.46 | 2019 | |
| Pfizer INC. | $112.73 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $94.96 | 2019-2024 | Jot Dx |
| Scpharmaceuticals INC. | $92.47 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $29.29 | 2019 | |
| Gilead Sciences, INC. | $21.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Schwarzwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.